Introduction
The POU family of transcription factors is based on the homologous DNA-binding domain of three mammalian transcription factors Pit-1, Oct-1, and Oct-2, and also the Caenorhabditis elegans protein Unc-86. A number of other proteins have been added to this growing family, and each is critical for normal development. Although Oct-1 is ubiquitously expressed, the majority of POUdomain transcription factor family members display a tissue-and developmental-restricted expression pattern. Oct-2 is expressed in B cells, activated T cells, macrophages, and neuronal cells (Staudt et al., 1988; He et al., 1989; Kang et al., 1992; Dunn et al., 1996) . Gene-targeting experiments have shown that in addition to their importance in normal embryonic development, these factors are also essential for the determination of cell fate. Loss of Oct-1, for example, is detrimental to normal erythropoiesis (Wang et al., 2004) while Oct-2 deletion affects terminal B-cell differentiation (Corcoran et al., 1993) .
The Oct factors mediate gene expression by binding to the octamer DNA element, ATGCAAAT, as well as to other similar regulatory sequences (LeBowitz et al., 1989; Poellinger and Roeder, 1989) . The octamer motif was identified first in the promoters of immunoglobulin (Ig) genes. Both Oct-1 and Oct-2 interact with a B-cellspecific cofactor called Bob-1, OCA-B or OBF-1, which was believed to facilitate B-cell-specific Ig expression. Although disruption of the Bob-1 locus resulted in the loss of germinal center formation and reduced levels of secondary Ig isotypes, B cells from Bob-1 À/À mice were similar to normal resting B cells (Kim et al., 1996; Nielsen et al., 1996; Schubart et al., 1996) . In addition, when mice were generated in which the lymphoid compartment was replaced with cells lacking both Oct-2 and Bob-1, B-cell development and Ig expression remained mostly unchanged, although there was a reduction in the mature peripheral B-cell population (Schubart et al., 2001) . Furthermore, when the lymphoid compartment of Rag À/À mice was reconstituted with Oct-1-deficient hematopoietic cells, the mice developed B cells displaying surface Ig levels similar to wild-type mice, but the number of B cells was reduced (Wang et al., 2004) . These studies suggested that the Oct factors and Bob-1 are not required for Ig expression as much as they are for cell fate determination and maintaining the B-cell population.
Recently, overexpression of Oct-2 and Bob-1 has been associated with a number of hematologic malignancies, including non-Hodgkin's lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and T-cell neoplasms (Greiner et al., 2000; regarding the role of these factors in malignant transformation. One possibility is that the Oct factors may be required for cell survival, however, there is currently little evidence in support of this hypothesis. Expression analysis studies with Bob-1-deficient B cells showed that Bob-1 targets genes responsible for B-cell proliferation and signaling (Kim et al., 2003) . In addition, Brunner et al. (2003) have shown that expression of the anti-apoptotic factor Bcl-2 is able to rescue early B lymphopoiesis, but not B-cell responsiveness in Bob-1-deficient mice. Although these studies indicate the importance of Bob-1 for mediating normal B-cell proliferation and survival signaling, the role of this factor and Oct-2 in malignant cells remains unclear.
Follicular lymphoma is the second most common form of non-Hodgkin's lymphoma and is characterized by the translocation of the bcl-2 proto-oncogene from 18q21 to the immunoglobulin heavy chain gene region at 14q32. This translocation results in deregulated expression of bcl-2 mediated both by the immunoglobulin enhancers and the bcl-2 regulatory region, which then leads to increased survival of t(14;18) lymphoma cells. The bcl-2 regulatory region is composed of two promoters, the 5 0 P1 promoter and the 3 0 P2 promoter. The P1 promoter is located approximately 1.4 kb upstream of the translational start site and is a TATA-less, GC-rich region displaying numerous transcriptional start sites (Seto et al., 1988) . The major regulatory elements in this region are a cAMP response element, and SP1-and WT1-binding sites (Wilson et al., 1996; Heckman et al., 1997 Heckman et al., , 2002 . The transcriptional start sites of the P2 promoter are 1.3 kb downstream of the P2 promoter. This promoter contains a canonical TATA element and is positively regulated by factors such as Myb, Cdx2, Aiolos, and C/EBP (Frampton et al., 1996; Taylor et al., 1996; Grassilli et al., 1999; Romero et al., 1999; Heckman et al., 2000 Heckman et al., , 2003b . In normal B cells, only the P1 promoter is active, however, in t(14;18) lymphoma cells, transcription also occurs from the P2 promoter. P2 promoter activation in t(14;18) lymphoma cells is dependent on the Ig enhancer sequences as well as the presence of transcription factors that are not expressed in normal B cells such as A-Myb, Cdx2, and C/EBPa (Heckman et al., 2000 (Heckman et al., , 2003a .
In these studies we show that t(14;18) lymphoma cells display increased levels of Oct-2 and Bob-1. We found that small-interfering RNA (siRNA) targeting of the Oct factors in t(14;18) lymphoma cells resulted in decreased levels of bcl-2 mRNA and increased apoptosis. Furthermore, Oct-2 is a strong activator of the bcl-2 P2 promoter and directly interacted with the bcl-2 regulatory region in vitro and in vivo. Oct-2 may therefore play an important role in malignant transformation by directly activating the expression of an antiapoptotic factor.
Results
Increased Oct-2 and Bob-1 levels in t(14;18) lymphoma cells The expression of Oct-2 in B cells varies with the stage of development and is inducible in precursor B cells as well as T cells (Miller et al., 1991; Kang et al., 1992; Bendall et al., 1997) . A similar pattern of expression is observed for Bob-1 (Sauter and Matthias, 1997) . For these studies, we performed Western analysis on two t(14;18) lymphoma cells lines, DHL-4 and DHL-6 and three primary t(14;18) lymphoma samples. As a comparison, we also examined the mature B-cell line DHL-9 and the pre-B-cell line Nalm-6. As expected, Oct-1 was expressed in all four cell lines and the three lymphoma samples, however, blotting for Oct-2 showed very high levels of this protein in the two t(14;18) lymphoma cell lines and the t(14;18) lymphoma samples, while little to no Oct-2 was observed in DHL-9 and Nalm-6 cells ( Figure 1 ). Slightly increased levels of Bob-1 were also observed in the t(14;18) lymphoma cells as compared to the other B-cell lines (Figure 1 ). Since the DHL-4 and DHL-6 cell lines and the lymphoma samples contain the t(14;18) translocation, these cells express much higher levels of Bcl-2 than other cell types ( Figure 1 ). As a loading control, the presence of the NF-kB family member p52 was also assessed (Figure 1 ). These results show that cells with the t(14;18) translocation and increased Bcl-2 expression also display greatly increased levels of Oct-2.
siRNA against the Oct factors decreases bcl-2 expression To determine the role of the Oct factors in t(14;18) lymphoma cells, we constructed siRNA molecules to target Oct-1, Oct-2, and Bob-1 expression. DHL-4 cells were transfected with the siRNA molecules along with a plasmid-encoding EGFP, allowed to recover, and the GFP-positive cells were collected by cell sorting. The GFP-positive cells were then lysed, and cDNA was prepared. As shown in Figure 2 , the siRNA molecules reduced the level of their corresponding mRNA as Figure 1 Expression of Oct-1, Oct-2, and Bob-1 in human B-cell lines and lymphoma samples. DHL-4 and DHL-6 cells contain the t(14;18) translocation, DHL-9 cells represent a mature stage of B-cell development and lack the translocation, while Nalm-6 cells represent an immature B-cell line and also lack the t(14;18) translocation. Primary t(14;18) lymphoma samples are shown in lanes 1-3. Nuclear extracts of the indicated cells were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose. The blot was probed with antibodies specific for the Oct-1, Oct-2, Bob-1, and Bcl-2 proteins. Probing for p52 was carried out to ensure equivalent protein loading.
Oct-2 regulates Bcl-2 expression CA Heckman et al measured by real-time PCR (Figure 2a ) and protein ( Figure 2b ) and in comparison to cells transfected with a nonspecific siRNA molecule. The transfected DHL-4 cells were also assessed for bcl-2 expression. Oct-1 and Oct-2 siRNA induced 25 and 40% decreases in bcl-2 mRNA levels, respectively, while Bob-1, and a combination of Oct-1 and Oct-2 siRNA reduced bcl-2 expression by approximately 50% each (Figure 2c ). For comparison, siRNA against bcl-2 reduced the level of its corresponding mRNA by 78% (Figure 2c ). These studies indicate that expression of Oct factors and Bob-1 correlates with the level of expression of bcl-2 and suggests that bcl-2 expression may be dependent on the Oct transcription factors.
Oct factors are required for t(14;18) lymphoma cell survival Since the Oct-and Bob-1-specific siRNAs reduced the level of endogenous bcl-2 mRNA in DHL-4 cells, we wanted to assess their effects on apoptosis. Cells with the t(14;18) display prolonged cell survival due to increased Bcl-2 levels and eventually acquire secondary mutations leading to transformation (McDonnell and Korsmeyer, 1991; Lossos and Levy, 2000) . Again DHL-4 cells were transfected with the Oct-, Bob-1-, or Bcl-2-specific siRNA molecules along with the farnesylated version of EGFP. The transfected cells were allowed to recover and then fixed and permeabilized. These were labeled with Br-dUTP and stained with an anti-BrdUTP antibody (Figure 3a) . Oct-1 and Oct-2 siRNA molecules both induced approximately a three-to fourfold increase in apoptosis as compared to cells transfected with a nonspecific siRNA (Figure 3b ). The Oct-1 and Oct-2 combination and Bob-1 induced fiveand 5.5-fold increases in apoptosis, respectively ( Figure  3a and b), while a siRNA targeting bcl-2 induced a 6.5-fold increase in apoptosis (Figure 3b ). Similar results were obtained for DHL-6 cells as well (data not shown). These data indicate that the Oct factors are not only required for bcl-2 expression, but also for t(14;18) lymphoma cell survival.
Transactivation of the bcl-2 promoter by Oct-2 To determine if the Oct factors and Bob-1 mediate their effect on bcl-2 expression and apoptosis by acting through the bcl-2 promoter region, we performed cotransfections of DHL-4 cells using a firefly luciferase reporter gene driven by the human bcl-2 regulatory sequences and cDNA expression vectors encoding the Oct factors or Bob-1. The full-length bcl-2 regulatory Figure 2 Inhibition of Oct-1, Oct-2, Bob-1, and Bcl-2 expression by RNA interference. (a) DHL-4 cells were transfected with 10 nM nonspecific siRNA or siRNA targeting Oct-1, Oct-2, or Bob-1 along with 1 mg of EGFP expression vector. The cells were allowed to recover for 24 h then sorted by GFP expression, and the GFP-positive cells collected and lysed. cDNA was prepared from the lysate and analysed by real-time reverse-transcriptase PCR. Oct-1, Oct-2, and Bob-1 expression was assessed using specific primers along with a fluorescently labeled probe. For normalization, values were adjusted to GAPDH levels and relative expression levels based on the nonspecific siRNA control. (b) DHL-4 cells were transfected with 10 nM siRNA as described in (a), and the cells were sorted by GFP expression, lysed, and the protein extract was electrophoresed on a SDS-polyacrylamide gel and transferred onto nitrocellulose. Detection was performed with the indicated antibodies, and b-actin was assessed to assure uniform loading. (c) DHL-4 cells were transfected with a nonspecific siRNA or siRNA targeting Oct-1, Oct-2, Bob-1, Bcl-2 or both Oct-1 and Oct-2 siRNA together and with the EGFP expression vector. Transfected cells were processed as described above, and the cDNA was analysed by real-time reverse transcriptase PCR using a fluorescent primer/probe set specific for Bcl-2. Relative bcl-2 mRNA levels were calculated based on GAPDH expression and the nonspecific control.
Oct-2 regulates Bcl-2 expression CA Heckman et al sequence contains both the P1 and P2 promoters, and several different transcription factors regulate the activity of each promoter ( Figure 4a ). When this reporter construct was transfected into DHL-4 cells with the Oct-1 expression vector, only a 20% increase in luciferase activity was observed ( Figure 4a ). However, transfection of the Oct-2 expression vector resulted in a 7.8-fold increase in luciferase activity while the Bob-1 expression vector induced a 3.8-fold increase ( Figure 4a ). In contrast, none of these expression vectors induced a significant increase in the bcl-2 promoter activity when transfected into DHL-9 cells ( Figure 4b ). To determine which bcl-2 promoter was activated by the Oct factors and Bob-1 in DHL-4 cells, the cDNA expression vectors were cotransfected into DHL-4 cells with reporter constructs containing sequences representing either the P1 or P2 regulatory regions ( Figure 4c ). As shown in Figure 4c , the expression vectors had little effect on luciferase activity from the P1 promoter construct, however, Oct-2 was able to induce a dramatic increase in P2 promoter activity, clearly indicating that Oct-2 acts through the Oct-2 regulates Bcl-2 expression CA Heckman et al bcl-2 P2 promoter. In addition, the Bob-1-induced bcl-2 activity was primarily mediated through the P2 promoter. The bcl-2 regulatory region, especially the P2 promoter, contains many potential octamer elements or sequences similar to this motif. Several deletions of the P2 promoter were generated to determine which of these sequences is required for Oct-2-mediated transactivation of bcl-2 (Figure 5a ). Transfection of these deletion constructs with the Oct-2 expression vector revealed that more than one site was required for Oct-2 transactivation. These sites were between sequences À1278 to À1257, À324 to À297 and sequences downstream of À98 (Figure 5b ). The ability of Oct-2 to greatly increase the activity of the À1180 construct compared to the À1257 construct as well as the P2 promoter construct compared to the full-length construct may be due to the presence of negative regulatory elements within the deleted regions such as the p-or WT1-binding sites (Chen and Boxer, 1995; Heckman et al., 1997) . Nevertheless, through these studies Oct-2 was found to increase bcl-2 promoter activity and act through sequences in the P2 regulatory region.
Direct interaction of Oct factors with bcl-2 regulatory sequences Interestingly, none of the regions that were activated by Oct-2 in the reporter gene studies contained a canonical octamer sequence. Instead, these sequences represented previously identified elements that mediate the activation of bcl-2 by other transcription factors, namely C/ EBP, A-Myb, and Cdx2 (Heckman et al., 2000 (Heckman et al., , 2003b . In addition, the known positive regulatory element in the À98 construct is the TATA site. These sequences are represented in Figure 6a with the binding sites in bold and underlined. To determine if the Oct factors interact with these sequences in vitro, we performed electrophoretic mobility shift assays with labeled probes representing the sequences and nuclear extract from DHL-4 cells. Site A, representing a C/EBP-binding site between À1278 and À1257 generated a number of protein complexes upon incubation with nuclear extract, and complexes 1-4 were competed with a 100-fold excess of unlabeled wild-type probe (Figure 6b , lanes 1 and 2). Competition of the specific complexes was not observed with the addition of a 100-fold excess of a sequence containing a mutation to the C/EBP site or with a nonspecific sequence (Figure 6b, lanes 3 and 4) . The addition of an antibody specific for Oct-1 resulted in the super-shift of complex 3 and inhibition of formation of complexes 1, 2, and 4 ( Figure 6b , lane 5). Incubation with an Oct-2-specific antibody also resulted in the inhibition of complex formation (complexes 1 and 2), while a Bob-1-specific antibody decreased the intensity of complexes 2 and 4, indicating some interference (Figure 6b, lanes 6 and 7) . Incubation of DHL-4 nuclear extract with a labeled probe, representing site B, also resulted in protein/DNA complex formation (Figure 6c, lane 1) . Competition with a 100-fold excess of unlabeled wild-type probe resulted in competition of specific complexes 1-5 that was not observed with the addition of a 100-fold excess of a mutated sequence or a nonspecific sequence (Figure 6c,  lanes 2-4) . The addition of an Oct-1 antibody resulted in a super-shift of specific protein/DNA complex 5 and inhibited the formation of complexes 1, 2, and 4 ( Figure 6c, lane 5) . The presence of an Oct-2 antibody caused a super-shift and decreased the intensity of complexes 3 and 5 (Figure 6c, lane 6) . The addition of a Bob-1-specific antibody or a nonspecific antibody did not induce any changes in complex formation (Figure 6c , lanes 7 and 8). A labeled probe, representing site C, also formed specific complexes when incubated with DHL-4 nuclear extract, and these could be competed with a 100-fold excess of unlabeled wild-type probe, but not with a 100-fold excess of a mutant or nonspecific sequence (Figure 6d, lanes 1-4) . The addition of an Oct-1 antibody resulted in a super-shift of complex 1, while an antibody to Oct-2 caused a super-shift of complex 2, neither of which was observed with the addition of the Bob-1 or nonspecific antibodies (Figure 6d, lanes 5-8) . These results indicate that both Oct-1 and Oct-2 interact in vitro with the Oct-2-responsive regions in the bcl-2 P2 promoter.
To determine if the Oct factors and Bob-1 interact with the bcl-2-regulatory region in vivo, we performed Oct-2 regulates Bcl-2 expression CA Heckman et al chromatin immunoprecipitation (ChIP) using the Oct-1, Oct-2, and Bob-1-specific antibodies and crosslinked chromatin derived from both DHL-4 and DHL-6 cells. Figure 7a is a schematic representation of the bcl-2 P2 promoter sequences with arrows indicating the approximate location of the PCR primers used in the assays.
(The control primers for the irrelevant region of the bcl-2 promoter are located between sites A and B.) Immunoprecipitation with the Oct-1 antibody resulted in the pull-down of the sequence containing site A and to a lesser extent site B in both DHL-4 and DHL-6 cells ( Figure 7b and c, respectively), while Oct-1 interaction with site C was not observed compared to the positive control of total input and negative controls of no chromatin, no antibody, and IgG (Figure 7b and c) . The Oct-2 antibody, however, precipitated all three sites, and the Bob-1 antibody precipitated sites A and B while only faint bands were observed with site C (Figure 7b and c). The probe and cold competitors are described in the Materials and methods. Lane 1, no competition; lane 2, 100-fold molar excess of unlabeled site C; lane 3, 100-fold molar excess of a sequence with a mutation to the TATA element; lane 4, 100-fold molar excess of a nonspecific sequence; lanes 5-8, antibodies specific for Oct-1, Oct-2, Bob-1, or a nonspecific protein, respectively. Arrows with 'SC' designate specific complexes and arrows with 'SS' indicate super-shifted complexes.
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Sites B and C are in close proximity to each other, and as the chromatin was sheared to an average length of 500 bp, it is likely that these sites were pulled down together with the Oct-2 and Bob-1 antibodies. However, these results provide a clear indication of the in vivo interaction of the Oct and Bob-1 factors with the bcl-2 P2 promoter. As shown for DHL-6 cells, there was no precipitation of the control site in an irrelevant region of the bcl-2 promoter by any of the antibodies (Figure 7c ).
C/EBP and Cdx-binding sites are required for Oct-2 transactivation of bcl-2 The regions that interact with the Oct and Bob-1 factors by deletion analysis and binding assays did not contain octamer consensus sequences. Nevertheless, to show that these sites were required for Oct-2 transactivation of the bcl-2 P2 promoter, we created a reporter construct containing mutations to the C/EBP and Cdx-binding sites (Figure 8 ). The TATA sequence was left intact because it is essential for basal promoter activity. When this mutated construct was transfected into DHL-4 cells with the Oct-2 expression vector, the ability of Oct-2 to activate bcl-2 P2 promoter activity was vastly reduced compared to the induction of the wild-type promoter construct (Figure 8 ). The remaining activity was likely due to the presence of the TATA sequence in the mutated construct. From these studies, we conclude that the C/EBP and Cdx sites are required for Oct-2 activation of bcl-2.
Discussion
Although the function of the Oct transcription factors and their cofactor Bob-1 has been extensively studied in normal B-cell development, little is known of their roles in malignant transformation. Recent reports indicated that Oct-2 and Bob-1 are highly expressed at the protein level in certain types of hematological malignancies compared to the normal cell counterpart, and we confirmed the increased expression of these two factors in t(14;18) lymphoma cells. Gene expression profiling of t(14;18) lymphoma cells has not revealed increased expression of Oct or Bob-1 mRNA, so it is likely that the augmented expression of these factors does not occur at the transcriptional level (Husson et al., 2002; Robetorye et al., 2002) . Both Oct-2 and Bob-1 are Oct-2 regulates Bcl-2 expression CA Heckman et al post-translationally modified, and this may contribute to their stability and activity in t(14;18) lymphoma cells (Tanaka and Herr, 1990; Grenfell et al., 1996; Inamoto et al., 1997; Zwilling et al., 1997) . In addition, there are a number of Oct-2 isoforms that result from alternative splicing, which may also lead to more stable Oct-2 expression (Wirth et al., 1991; Annweiler et al., 1994) . Preliminary analysis of Oct-1, Oct-2, and Bob-1 expression by real-time reverse transcriptase PCR showed no difference at the RNA level between DHL-4, DHL-6, DHL-9, and Nalm-6 cells (data not shown). It will also be interesting and important in the future to elucidate the mechanism for augmented Oct-2 and Bob-1 expression in lymphoma cells as well as in other malignancies. The function of the Oct factors and Bob-1 in malignant cells has not been investigated previously, however, gene disruption studies indicated that these factors are essential for normal development and cell survival. We used RNA interference to decrease the expression of the Oct factors and Bob-1 in t(14;18) lymphoma cells and to establish their function in this cell type. Targeting of Oct-1 or Oct-2 resulted in reduced bcl-2 expression, and apoptosis was induced in t(14;18) lymphoma cells. This was further enhanced by targeting both Oct-1 and Oct-2 together or Bob-1 alone. As it is likely that the increased level of Oct-2 and Bob-1 in t(14;18) lymphoma cells results from post-translational modifications, the use of specific siRNA molecules may not fully inhibit the expression of these genes. Although the level of expression of the Oct and Bob-1 proteins was markedly reduced by siRNA, we found that expression was not completely extinguished. Therefore, the reduced level of bcl-2 mRNA and the amount of apoptosis induced by the Oct-and Bob-1-specific siRNA was not as great as that observed when using a bcl-2-specific siRNA. In addition, other transcription factors that activate bcl-2 expression in t(14;18) lymphoma cells remain functional. However, these studies do provide evidence indicating that the Oct factors and Bob-1 are required for t(14;18) lymphoma cell survival and that they mediate this function in part by regulating the expression of the antiapoptotic factor bcl-2.
There was no previous evidence demonstrating that the Oct factors directly regulate the expression of an antiapoptotic gene. However, Brunner et al. (2003) did find that Bob À/À mice displayed reduced levels of bcl-2 mRNA and that Bcl-2 was capable of rescuing the early stages of B-cell development in those mice, although there was no indication of a direct link between Bob-1 and bcl-2 gene regulation. We found that Bob-1 was able to activate a reporter construct containing the bcl-2 regulatory region in malignant B cells. Moreover, we found that Oct-2 was a powerful inducer of the bcl-2 promoter and acted through the 3 0 P2 promoter region. Although the Oct-2-responsive regions as identified through deletion analysis did not contain canonical octamer sequences, these sites have been characterized previously and are known to bind factors that interact with Oct-1 or Oct-2. The most 5 0 Oct-2-responsive sequence is required for C/EBP regulation of bcl-2, as is the second sequence, which represents a Cdx homeodomain protein-binding site (Heckman et al., 2003b) . The Cdx site also mediates the ability of A-Myb to induce bcl-2 promoter activity (Heckman et al., 2000) . The last Oct-2-responsive site, which contains the TATA sequence, is required for basal transcriptional activity (Wu et al., 2001) . Certain isoforms of C/EBPb interact with both Oct-1 and Oct-2 on Ig heavy and light chain promoters, as well as in the absence of DNA, although this interaction was thought to interfere with transcriptional activation (Hatada et al., 2000) . Oct-1 interacts with the Myb DNA-binding domain of the basal transcription factor SNAPc, and Oct-1 acts to recruit the TATA-binding protein TBP to a TATA box (Wong et al., 1998; Bertolino and Singh, 2002) . In addition, Oct-1 can directly activate expression of Cdx2 (Jin and Li, 2001) , another gene that is ectopically expressed in t(14;18) cells (Heckman et al., 2000) . When DHL-9 cells, which do not express C/EBPa, Cdx2, or A-Myb, were transfected with the Oct-2 expression vector and bcl-2 reporter constructs, we did not observe an increase in promoter activity, suggesting that Oct-2 requires the presence of other factors to regulate bcl-2 expression in t(14;18) lymphoma cells.
By EMSA, we showed that both Oct-1 and Oct-2 interacted with the three Oct-2-responsive regions in the bcl-2 promoter in vitro. However, it was not clear if Bob-1 was also present in these complexes. By ChIP, we were able to detect the interaction of Bob-1 with the bcl-2 promoter in vivo, particularly with the region containing the Cdx-binding site. An Oct-1 antibody precipitated the regions with the C/EBP-and Cdx-binding sites, while an Oct-2 antibody precipitated regions containing all three sites. The ability of Oct-2 to interact with a number of regions in the P2 promoter may provide an explanation for the strong induction of the bcl-2 promoter reporter construct by an Oct-2 expression vector as compared to the Oct-1 or Bob-1 vectors. In addition, these results provide the first evidence demonstrating the direct interaction of the Oct and Bob-1 factors with the bcl-2 promoter in vitro and in vivo.
Using a mutated reporter construct, we found that the C/EBP-and Cdx-binding sites were required for Oct-2 to activate the bcl-2 P2 promoter. Although the TATA site was not mutated, it is likely that this site mediated the remaining activity of Oct-2 on the mutated construct. The activity observed with this construct was similar to that of the minimal deletion construct, which primarily consisted of the TATA site and downstream sequences and did not contain octamer motifs or other protein-binding sites. Although only the bcl-2 P1 promoter is active in normal B cells, additional transcriptional activity from the P2 promoter occurs in t(14;18) lymphoma cells (Wu et al., 2001) . The increased expression of Oct-2 in t(14;18) lymphoma cells and its ability to interact with the P2 promoter region may explain the activation of the bcl-2 P2 promoter in this cell type. However, it is likely that Oct-2 is able to interact with other sequences affecting bcl-2 expression in t(14;18) lymphoma cells, especially those of the Ig enhancer (Sepulveda et al., 2004) . Nonetheless, increased expression of Oct-2 and Bcl-2 is observed in other malignancies that lack this translocation, and it is probable that Oct-2 affects bcl-2 expression in those cell types as well by directly interacting with the bcl-2 promoter.
Our studies provide new evidence that the Oct factors and the Oct cofactor Bob-1 mediate cell survival in t(14;18) lymphoma cells by directly activating the antiapoptotic gene bcl-2, and they may therefore play a role in malignant transformation. This activation appears to be complex and involves interactions with other transcriptional mediators. In addition, as genetargeting studies have shown that the Oct factors and Bob-1 are required for normal embryonic development and cell fate, it is possible that the bcl-2 gene is a target of these factors in normal cells during development.
Other genes that are required for survival or cell proliferation may also be targets for these transcription factors. The gene-targeting studies, along with the results presented here, suggest that a primary role of the Oct factors is to act as cell-survival factors in normal and malignant development.
Materials and methods
Cell lines and samples Nalm-6, and DHL-9 are human B-cell lines that have been described previously (Chen and Boxer, 1995; Ji et al., 1996; Wilson et al., 1996) . DHL-4 and DHL-6 are human B-cell lines containing the t(14;18). All cells were maintained in RPMI medium with 10% fetal calf serum, L-glutamine, penicillin, and streptomycin. The t(14;18) lymphoma samples were obtained from patients after informed consent using a protocol approved by the human subjects IRB. The samples were purified and stored as frozen viable cells (Meeker et al., 1985) .
Western blot analysis
For expression of Oct transcription factors and Bcl-2 in B cells, total protein extracts were prepared from DHL-4, DHL-6, Nalm-6, DHL-9, and primary lymphoma cells by lysing cells in Triton X-100 extract buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na 4 P 2 O 7 , 2 mM Na 3 VO 4 , 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate, 1 mM PMSF). A total of 50 mg of protein was diluted with 2 Â Laemmli buffer and loaded onto a 10% SDS-polyacrylamide gel, electrophoresed, and transferred onto nitrocellulose. Detection of Oct-1, Oct-2, Bob-1, Bcl-2, and p52 was performed using antibodies from Santa Cruz Biotechnology. Western blotting luminol reagent from Santa Cruz Biotechnology was used for chemiluminescence detection.
Construction of siRNA siRNA molecules were synthesized using Ambion's Silencer siRNA Construction Kit. The primers used as templates are the following:
Oct-1 antisense: AACAATCCGTCAGAAACCAGTCCTGT CTC Oct-1 sense:
AAACTGGTTTCTGACGGATTGCCTGT CTC Oct-2 antisense: AAATAAGAATGTCTAAGCCCCCCTGT CTC Oct-2 sense:
AAGGGGCTTAGACATTCTTATCCTGT CTC Transfection of siRNA, selection of transfected cells, and cDNA preparation Transfection of DHL-4 cells with siRNA molecules along with an EGFP expression vector was performed as previously described (Heckman et al., 2003b) . GFP-positive cells were sorted using a FACSVantage SE cell sorter (BD Biosciences), collected in supplemented RPMI medium, washed twice with PBS, and cDNA was prepared from 10 000 cells using Ambion's Cells-to-cDNA kit or protein was prepared as described above.
Quantitation of mRNA expression by real-time PCR Real-time PCR was performed on the cDNA using the ABI Prism 7900-HT Sequence Detection System (Applied Biosystems). Each PCR reaction was composed of 1 ml cDNA, 5 ml 2 Â Universal Master Mix (Applied Biosystems), 0.5 ml 20 Â primer/probe mix and 3.5 ml H 2 O. For the no template controls, the cDNA was replaced with nuclease-free H 2 O. All primer/probe sets were purchased from Applied Biosystems either as an Assays-on-Demand gene expression product or as a predeveloped assay reagent. Values for Oct-1, Oct-2, Bob-1, and Bcl-2 were first normalized to the GAPDH value for the same sample to control for loading differences. Relative expression was then calculated based on the normalized value for the nonspecific siRNA sample. The results represent the averaged values from three independent experiments.
Measurement of apoptosis by TUNEL assay
The terminal deoxynucleotidyltransferase (TdT) dUTP nick end labeling (TUNEL) technique was used to quantify apoptosis using a modified BD Bioscience APO-BrdU kit. For this assay, DHL-4 cells were transfected with siRNA as described above, except that the farnesylated version of EGFP (pEGFP-F from Clontech) was used as the selection marker. Transfected cells were incubated for 48 h and then fixed and permeabilized with 1% paraformaldehyde and 70% ethanol. DNA ends were labeled with Br-dUTP using TdT. Labeled DNA was detected using Alexa-Fluor 647 anti-Br-dUTP (Molecular Probes). Analyses were performed on the FACS Caliber (BD Bioscience) flow cytometer. The results represent three or more independent experiments.
Plasmid constructs
The bcl-2 promoter-luciferase reporter constructs have been described previously (Wilson et al., 1996; Heckman et al., 2000) . Deletions of the bcl-2 5 0 flanking sequence were made by PCR subfragment cloning or by insertion of restriction enzyme sites by site-directed mutagenesis (Stratagene) followed by subfragment cloning. The C/EBP and Cdx sites were mutated in the À1278 construct as described previously (Heckman et al., 2003b) . The Oct-1 and Oct-2 expression vectors consisted of the human full-length coding regions under the control of the cytomegalovirus (CMV) immediate early promoter and were kindly provided by Dr Daniel Tenen. The Bob-1 expression vector encoded the human cDNA sequence regulated by the CMV promoter and was a generous gift from Dr Winship Herr. The empty control vector also contained the CMV promoter.
Luciferase reporter assays
Luciferase reporter assays were carried out as previously reported (Heckman et al., 2003b) . Reporter gene activity was assessed using the Dual-Luciferase Assay System (Promega) on a Femtomaster FB 12 luminometer (Zylux). Results were normalized to renilla luciferase activity and represent at least four independent transfections.
EMSA
The double-stranded oligonucleotides used for EMSA of the three Oct-2-responsive regions in the bcl-2 P2 promoter are shown below. The mutated sequences are shown in boldface. The oligonucleotides were synthesized with 5 0 -overhangs, annealed, and labeled with [a-32 P]dCTP and Klenow polymerase. The binding conditions have been described previously (Heckman et al., 2000) . For DNA competition experiments, a 100-fold molar excess of unlabeled oligonucleotide was added prior to the 20 min room temperature incubation with nuclear extract and labeled probe. For the super-shift experiments, 4 mg of antibody was added to the completed binding reaction, and this was incubated for 1 h at 41C. All antibodies were acquired from Santa Cruz Biotechnology. Electrophoresis was performed in a 0.5 Â Tris borate-EDTA 5% polyacrylamide gel at 20 mA and 41C.
ChIP assay
The ChIP assay was performed as described previously (Heckman et al., 2003a) . Precipitation of bcl-2 promoter regions was assessed by PCR amplification using 1 ml of each sample. For PCR amplification, the following oligonucleotide sequences were used as primers: The control (Irr) site lacks transcriptional activity (Heckman et al., 2003b) . PCR products were resolved on 2% agarose gels and visualized by ethidium bromide staining.
